Quale sarebbe il prezzo per Biora Therapeutics, Inc. (PROG)

Il prezzo per Biora Therapeutics, Inc. (PROG) è $0.8845

Qual è la capitalizzazione di mercato per Biora Therapeutics, Inc. (PROG)

La capitalizzazione di mercato per Biora Therapeutics, Inc. (PROG) è $31.01M

Biora Therapeutics, Inc. (PROG) Prezzo e Capitalizzazione di Mercato

Biora Therapeutics, Inc., a biotechnology firm, focuses on the development and commercialization of molecular diagnostic products within the United States. Its research and development efforts include targeted oral delivery systems for biotherapeutics, such as PGN-600, an oral liquid formulation of tofacitinib for ulcerative colitis, and PGN-001, an orally administered variant of adalimumab also targeting ulcerative colitis. Beyond this, the company is advancing systemic oral biotherapeutic delivery, exemplified by PGN-OB, which combines an adalimumab variant with their Oral Biotherapeutics Delivery System (OBDS) for inflammatory conditions, and PGN-OB2, pairing a GLP-1 receptor agonist with the OBDS for Type 2 diabetes. Biora Therapeutics also creates innovative diagnostic tools, including the Recoverable Sampling System – an ingestible smart capsule engineered to autonomously locate, collect, and preserve samples from the GI tract for analysis – and PIL Dx, another ingestible smart capsule designed to sample, measure, and transmit data wirelessly. A collaboration with Ionis Pharmaceuticals is underway to assess the OBDS platform for delivering antisense oligonucleotides. Founded in 2010 as Ascendant MDX, Inc., the company adopted the name Progenity, Inc. in November 2013, prior to becoming Biora Therapeutics, Inc. Its headquarters are located in San Diego, California.

Il prezzo per PROG	Attivo B	Capitalizzazione del mercato a B	Risultati
$151,171 $31.01M	NVDA	$5.301T	+17,091,039.23%
$132,150 $31.01M	AAPL	$4.634T	+14,940,488.01%
$118,150 $31.01M	GOOG	$4.143T	+13,357,761.72%
$102,362 $31.01M	MSFT	$3.589T	+11,572,810.28%
$81,474.99 $31.01M	AMZN	$2.857T	+9,211,317.27%

Il prezzo per PROG

Attivo B

Capitalizzazione del mercato a B

Risultati

$151,171 $31.01M